CAM
SRPT icon

Clarity Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Clarity Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$1.6K – 265
2025
Q1 		$1.6K Hold
25
– – ﹤0.01% 203
2024
Q4 		$3.04K Hold
25
– – ﹤0.01% 192
2024
Q3 		$3.12K Hold
25
– – ﹤0.01% 173
2024
Q2 		$3.95K Hold
25
– – ﹤0.01% 162
2024
Q1 		$3.24K Hold
25
– – ﹤0.01% 176
2023
Q4 		$2.41K Buy
+25
New +$2.4K ﹤0.01% 176

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Clarity Asset Management's SRPT Position: Q2 2025 in Review

Clarity Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 25 shares — an estimated $1.6K sold.

Clarity Asset Management first reported a position in SRPT in Q4 2023 and held it in 6 quarters. The position peaked at $3.95K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Clarity Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Clarity Asset Management sold 25 Sarepta Therapeutics shares in Q2 2025, an estimated $1.6K.
  • Clarity Asset Management first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 6 quarters.
  • Clarity Asset Management's Sarepta Therapeutics position peaked at $3.95K in Q2 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Clarity Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.